Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
The renewed commitment will provide continued preventative (prophylactic) treatment to as many as 1,000 people with haemophilia A in locations where there is little to no access to haemophilia treatment
The plan is to advance innovative therapies to drug-resistant cancers
To lay a technological foundation for developing exosome-based medicines and cosmetic products for dermatitis treatment
Takeda and United Nations Global Compact Network of India (UNGCNI) join hands
The new building is expected to be commissioned by 2024. Post the expansion, Nanavati-Max Hospital will be amongst the largest private sector hospital in western India
Ahead of International Thalassemia Day on 8th May, medical professionals and representatives of patient bodies participated in a virtual discussion on the current situation of Thalassemia management in India
There is a need for the Ministry of Health to put it on the priority list and address the issues, which are numerous
Upon closing, the Quakertown business will become an independent company called Microsize
Subscribe To Our Newsletter & Stay Updated
